Avalo Therapeutics (AVTX) Set to Announce Quarterly Earnings on Monday

Avalo Therapeutics (NASDAQ:AVTX) will announce its earnings results on Monday, November 6th.

Avalo Therapeutics (NASDAQ:AVTX) last announced its earnings results on Thursday, August 3rd. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.31. The company had revenue of $0.64 million for the quarter, compared to analyst estimates of $1.00 million. On average, analysts expect Avalo Therapeutics to post $-4 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Avalo Therapeutics Stock Performance

Shares of AVTX opened at $0.10 on Friday. The company has a market capitalization of $2.09 million, a PE ratio of -0.05 and a beta of 1.22. Avalo Therapeutics has a 12 month low of $0.08 and a 12 month high of $7.00. The stock’s 50-day moving average price is $0.13 and its two-hundred day moving average price is $1.19.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Susquehanna International Group LLP acquired a new position in shares of Avalo Therapeutics in the 4th quarter valued at about $95,000. Renaissance Technologies LLC lifted its stake in shares of Avalo Therapeutics by 819.1% in the 1st quarter. Renaissance Technologies LLC now owns 367,193 shares of the company’s stock valued at $266,000 after purchasing an additional 327,241 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Avalo Therapeutics by 23.8% in the 2nd quarter. Goldman Sachs Group Inc. now owns 649,653 shares of the company’s stock valued at $324,000 after purchasing an additional 124,769 shares during the period. Braidwell LP acquired a new position in shares of Avalo Therapeutics in the 1st quarter valued at about $433,000. Finally, Millennium Management LLC acquired a new position in shares of Avalo Therapeutics in the 2nd quarter valued at about $506,000. 19.28% of the stock is owned by institutional investors and hedge funds.

Avalo Therapeutics Company Profile

Avalo Therapeutics, Inc, a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation. The company's drug candidates include AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as Crohn's disease; Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome; and AVTX-008, a fully human B and T Lymphocyte Attenuator (BTLA) agonist fusion protein.